Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Burg Pharma GmbH Overview
Burg Pharma GmbH is a reputable pharmaceutical intermediary based in Bernburg (Saale), Saxony-Anhalt. The company was founded in 2003 and has since established itself as a key player in the central German pharmaceutical sector. By utilizing the well-developed regional pharmaceutical infrastructure characterized by the chemical-pharmaceutical region around Halle and Bitterfeld, Burg Pharma is able to offer efficient services. The company specializes in mediating pharmaceutical transactions while considering the latest regulatory requirements in drug trafficking.
Pharmaceutical Mediation in Central Germany
Burg Pharma has specialized in mediating pharmaceutical transactions in the central German pharmaceutical wholesale market. The company acts as a link between manufacturers, importers, as well as pharmacies and wholesalers. A particularly noteworthy feature of Burg Pharma is that it does not operate its own warehousing. Instead, the company uses cooperative relationships with regional wholesalers to ensure swift and demand-oriented delivery of pharmaceuticals. This significantly contributes to efficiency and flexibility in drug trafficking.
A crucial part of Burg Pharma's business activities is compliance with all relevant legal requirements and pharmaceutical standards to guarantee the safety and quality of the mediated pharmaceuticals. The company closely cooperates with various regulatory authorities and ensures that all licensing and compliance requirements are fully met. This not only ensures the smooth execution of transactions but also strengthens its partners' trust in Burg Pharma's services.
Location Bernburg (Saale)
Bernburg on the Saale in Saxony-Anhalt has established itself as a traditional chemical-pharmaceutical location. The city offers a dense network of production sites, funding institutions, and research facilities that specialize in the development and manufacture of pharmaceutical products. Through this close connection to the local industry, Burg Pharma can optimally coordinate its mediation activities. The diverse development opportunities in this region contribute to the innovative power of Burg Pharma and support the company in selecting the best products for the market.
Additionally, Bernburg plays a central role in the regional economy. The city is part of the "Chemie-Tal" cluster and benefits from dynamic collaboration between companies, research institutions, and educational establishments. These synergies not only promote the development of new pharmaceuticals but also enable Burg Pharma to respond promptly to market changes and trends.
Special Features and Outlook
Burg Pharma GmbH stands out due to several special features. The company pursues a sustainable business strategy that aims not only for economic gains but also integrates social responsibility and environmental awareness. For example, the company is involved in local projects and supports educational initiatives in the field of pharmacy and chemistry. This not only creates a positive corporate image but also fosters the next generation of professionals in the region who are crucial for the future of the pharmaceutical sector.
In the coming years, Burg Pharma plans to further expand its services and increasingly focus on digital solutions. The application of modern technologies and digital platforms is intended to enhance efficiency in the pharmaceutical mediation industry and open up new markets. Through innovative approaches, the company aims to contribute to the healthcare economic development in Central Germany.
More pharmaceutical intermediaries in Germany | pharmaceutical intermediaries in Saxony-Anhalt | pharmaceutical wholesale in Germany
Frequently asked questions about Burg Pharma GmbH
Was ist ein Arzneimittelvermittler?
Arzneimittelvermittler sind nach § 52c AMG registrierte Unternehmen, die Transaktionen mit Arzneimitteln zwischen Herstellern, Großhändlern und Abgebern vermitteln, ohne selbst physisch in Besitz der Ware zu kommen.
Was macht Burg Pharma GmbH?
Burg Pharma GmbH ist ein registrierter Arzneimittelvermittler in Bernburg (Saale), Sachsen-Anhalt, der Transaktionen im pharmazeutischen Handel koordiniert und als Bindeglied zwischen Lieferanten und Abnehmern fungiert.
Wie erreiche ich Burg Pharma GmbH?
Adresse und Kontaktdaten von Burg Pharma GmbH in Bernburg (Saale), Sachsen-Anhalt finden Sie auf dieser Sanoliste-Seite.
Drug Brokers in Germany
Related areas in healthcare
Drug Brokers by location
About Drug Brokers
A medicine broker (Arzneimittelvermittler) is a business that arranges the purchase or sale of human medicines between manufacturers, wholesalers and buyers, acting as an intermediary without ever taking physical possession of or legal title to the products. This role is formally defined under Section 4(22b) of the AMG (German Medicinal Products Act). Medicine brokers play a role in international parallel trade and in secondary supply chains, but their activities are subject to strict legal requirements to prevent counterfeit medicines from entering the legitimate supply chain. In Germany, anyone wishing to act as a medicine broker must register with the competent authority of the relevant German federal state under Section 52b AMG. Registration requires a permanent business address in Germany or another EU member state, a designated responsible person, and a fully documented quality management system that meets the requirements of the EU Good Distribution Practice (GDP) guidelines for medicine brokers. Failure to register or to maintain the required quality system constitutes a criminal offence under German pharmaceutical law. The registration system ensures traceability and accountability throughout the supply chain. Medicine brokers must not procure medicines from unlicensed sources or supply non-authorised products. The GDP requirements specific to brokers include record keeping, complaint handling, recall procedures and counterfeiting detection. This directory lists all medicine brokers registered with German authorities under Section 52b AMG, with addresses and contact details.
Medicine Brokering in Germany: Legal Framework
Medicine brokering is a regulated activity in Germany and across the European Union, governed by the EU Falsified Medicines Directive (2011/62/EU) and its implementing measures, transposed into German law through amendments to the AMG. The formal definition of a medicine broker (Arzneimittelvermittler) is set out in Section 4(22b) AMG: a natural or legal person who arranges transactions involving medicinal products for human use between manufacturers, wholesalers and buyers, without themselves acquiring or supplying the products and without taking physical possession of them. This intermediary role distinguishes brokers from wholesalers. The registration requirement under Section 52b AMG was introduced specifically to increase transparency and traceability in the medicine supply chain, after investigations revealed that unlicensed brokers had been involved in the entry of substandard or falsified medicines into European supply chains. Germany's registration system requires brokers to notify the competent state authority before commencing operations and to maintain their registration as long as they are active.
GDP Quality System Requirements for Medicine Brokers
Although medicine brokers do not physically handle medicines, they are still required to operate a documented quality management system (QMS) under the EU GDP guidelines for brokers (2013/C 343/01, Part III). The QMS must cover several key areas: written procedures (SOPs) for all brokering activities, a system for verifying that all counterpart manufacturers and wholesalers hold the required licences, a complaints handling system for quality-related issues, a product recall procedure that can be activated even though the broker did not physically move the goods, record keeping for a minimum of five years for all brokered transactions, and procedures for detecting and reporting suspected falsified medicines to the competent authority. Brokers must not source from or supply to unlicensed parties. Regular self-inspections and, where relevant, external audits ensure the QMS remains effective. The competent state authority may inspect a broker's QMS as part of its oversight activities.
Medicine Brokering and Parallel Trade in the EU
Medicine brokering is closely associated with parallel trade (Parallelhandel) in the EU pharmaceutical market. Parallel trade occurs when an authorised medicine is purchased in an EU member state where its price is lower and resold in another member state where the price is higher, exploiting price differentials across the single market. Germany, as a large market with relatively higher medicine prices than some southern and eastern European member states, is a significant destination for parallel-traded medicines. Parallel importers must obtain a parallel import permit from BfArM or PEI for each product, ensuring the imported medicine is equivalent to the authorised German version. Medicine brokers can play a role in arranging these cross-border transactions. However, all parties in the parallel trade supply chain, including brokers, must comply with applicable GDP and registration requirements. The Falsified Medicines Directive's safety features (tamper-evident packaging and unique identifiers under the EU Falsified Medicines Verification System, EMVS) apply to all prescription medicines circulating in Germany.
Compliance and GDP Requirements for Brokers
Pharmaceutical brokers remain under strict regulatory oversight despite not handling products physically. A broker's GDP quality system must include procedures for order processing, supplier qualification, complaints management, recall management and self-inspections. All brokered medicinal products must originate from legal, officially approved sources; transaction documentation must be kept comprehensively and retained for at least five years. Suspected falsified medicines must be reported to the competent authority. The European Commission defined clear requirements for brokers without product ownership in GDP Guidelines 2013/C 343/01. Regular self-inspections and the designation of a Responsible Person (RP) are mandatory. Violations can result in deregistration and criminal consequences under the Medicines Act. The Sanoliste directory only lists brokers who were registered in accordance with Section 52b AMG at the time of their entry.
What does a medicine broker do?
A medicine broker, as defined under Section 4(22b) of the AMG (German Medicinal Products Act), arranges transactions in human medicines without taking ownership of the products or physically handling them. Brokers must be registered with the responsible authority and maintain a quality management system.
What registration does a medicine broker need?
Medicine brokers must register under Section 52b AMG with the responsible state authority. Requirements include an official business address in Germany and a documented quality system meeting GDP (Good Distribution Practice) standards.
Where can I find registered medicine brokers in Germany?
The competent state pharmaceutical supervisory authority in each federal state maintains a register of brokers registered under Section 52b AMG. Sanoliste provides a searchable overview of registered medicine brokers across Germany with contact details and addresses.
Why are medicine brokers regulated in Germany?
Regulation of medicine brokers in Germany is primarily aimed at preventing counterfeit and substandard medicines from entering the legitimate pharmaceutical supply chain. By requiring registration and a documented GDP quality system, authorities can trace the origin and movement of medicines arranged by brokers. This protects patients and ensures that only authorised medicines from authorised sources reach pharmacies and hospitals.
What are the GDP requirements for medicine brokers in Germany?
Under EU GDP guidelines (2013/C 343/01), medicine brokers must maintain a quality system that covers written procedures, complaint handling, product recall procedures, record keeping and measures to detect falsified medicines. They must only deal with manufacturers and wholesalers that hold the appropriate authorisations. These requirements apply equally to brokers registered in Germany under Section 52b AMG.
How does medicine brokering differ from pharmaceutical wholesale in Germany?
The key difference is physical possession. A pharmaceutical wholesaler (Pharmagrosshandel) physically stores and ships medicinal products and requires a wholesale dealer authorisation under Section 52a AMG. A medicine broker (Arzneimittelvermittler) never takes possession of the goods; it only acts as an intermediary arranging deals between other parties. Brokers require registration under Section 52b AMG rather than a full wholesale authorisation.